Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
BMC Health Serv Res ; 23(1): 156, 2023 Feb 15.
Article in English | MEDLINE | ID: mdl-36793080

ABSTRACT

BACKGROUND: The SARS-CoV-2 pandemic has resulted in an increase in telemedicine utilization for routine HIV care. However, there is limited information on perceptions of and experiences with telemedicine from United States (U.S.) federally qualified health centers (FQHCs) offering HIV care. We sought to understand telemedicine experiences of stakeholders with various roles: people living with HIV (PLHIV), clinical (clinicians and case managers), programmatic (clinic administrators), and policy (policymakers). METHODS: Qualitative interviews about benefits and challenges of telemedicine (telephone and video) for HIV care were conducted with 31 PLHIV and 23 other stakeholders (clinicians, case managers, clinic administrators, and policymakers). Interviews were transcribed, translated to English if conducted in Spanish, coded, and analyzed for major themes. RESULTS: Almost all PLHIV felt capable of engaging in telephone visits, with some expressing interest in learning how to use video visits as well. Nearly all PLHIV wanted to continue telemedicine as part of their routine HIV care, and this was also endorsed by clinical, programmatic and policy stakeholders. Interviewees agreed that telemedicine for HIV care has benefits for PLHIV, especially savings of time and transportation costs, which also reduced stress. Clinical, programmatic, and policy stakeholders expressed concerns around patients' technological literacy and resources, as well as their access to privacy, and some felt that PLHIV strongly preferred in-person visits. These stakeholders also commonly reported clinic-level implementation challenges, including integrating telephone and video telemedicine into workflows and difficulty with video visit platforms. CONCLUSIONS: Telemedicine for HIV care, largely delivered via telephone (audio-only), was highly acceptable and feasible for both PLHIV, clinicians, and other stakeholders. Addressing barriers for stakeholders in incorporating video visits will be important for the successful implementation of telemedicine with video as part of routine HIV care at FQHCs.


Subject(s)
COVID-19 , HIV Infections , Telemedicine , Humans , United States , Los Angeles , COVID-19/epidemiology , SARS-CoV-2 , Telemedicine/methods , HIV Infections/therapy
2.
Article in English | MEDLINE | ID: mdl-22930796

ABSTRACT

Nevirapine (NVP) was the first nonnucleoside reverse transcriptase inhibitor (NNRTI) approved by the US Food and Drug Administration (FDA) in 1996, for the treatment of HIV infection. Current treatment guidelines include NVP as a component of a recommended alternative NNRTI regimen, which may be the preferred regimen for patients with established cardiovascular risk factors since NVP has minimal untoward effects on serum lipids. Two randomized and controlled clinical trials established the noninferior virologic efficacy of twice-daily NVP versus ritonavir-boosted atazanavir (ATV/r), a protease inhibitor with limited effects on serum lipids, each drug on a background regimen of once-daily (QD) tenofovir (TDF)/emtricitabine (FTC). An extended-release (XR) formulation of NVP was developed since QD dosing and reduced pill burdens have been shown to improve regimen adherence. This formulation (Viramune XR 400 mg) was recently FDA approved based on the results of 2 randomized, controlled clinical trials. The XR formulation will provide additional treatment options for patients who may benefit from NVP-based regimens.


Subject(s)
Anti-HIV Agents/administration & dosage , HIV Infections/drug therapy , Nevirapine/administration & dosage , Reverse Transcriptase Inhibitors/administration & dosage , Anti-HIV Agents/adverse effects , Delayed-Action Preparations/administration & dosage , Delayed-Action Preparations/adverse effects , HIV Infections/virology , Humans , Nevirapine/adverse effects , Reverse Transcriptase Inhibitors/adverse effects , Viral Load
3.
J Intensive Care Med ; 24(3): 205-7, 2009.
Article in English | MEDLINE | ID: mdl-19460826

ABSTRACT

INTRODUCTION: Kombucha "mushroom'' tea is touted to have medicinal properties. Here, we present a case of hyperthermia, lactic acidosis, and acute renal failure within 15 hours of Kombucha tea ingestion. CASE PRESENTATION: A 22 year old male, newly diagnosed with HIV, became short of breath and febrile to 103.0F, within twelve hours of Kombucha tea ingestion. He subsequently became combative and confused, requiring sedation and intubation for airway control. Laboratories revealed a lactate of 12.9 mmol/L, and serum creatinine of 2.1 mg/dL. DISCUSSION: Kombucha tea is black tea fermented in a yeast-bacteria medium. Several case reports exist of serious, and sometimes fatal, hepatic dysfunction and lactic acidosis within close proximity to ingestion. CONCLUSION: While Kombucha tea is considered a healthy elixir, the limited evidence currently available raises considerable concern that it may pose serious health risks. Consumption of this tea should be discouraged, as it may be associated with life-threatening lactic acidosis.


Subject(s)
Acidosis, Lactic/chemically induced , Tea/toxicity , HIV Infections/complications , Humans , Male , Young Adult
4.
J Womens Health (Larchmt) ; 18(1): 127-31, 2009.
Article in English | MEDLINE | ID: mdl-19072725

ABSTRACT

BACKGROUND: Internists care for women of reproductive age, but little is known about internists' training in contraceptive counseling or provision of contraceptive methods. METHODS: We surveyed 152 residents in nine internal medicine programs in Los Angeles County during the 2004-2005 academic year. The self-administered, 29-item survey included demographic, contraceptive practice pattern, and training variables. Descriptive statistics and multivariable logistic regression were used to illustrate counseling and prescribing practices and to identify predictors of counseling and provision of contraceptives. RESULTS: Most (95%) future internists surveyed reported clinical responsibility for women of reproductive age. However, few (17%) routinely provided contraceptive counseling, and 39% rarely or never provided contraceptive counseling. Residents had prescribed contraception on a median of 2 (range 0-30) occasions in the past year. Some formal education in contraceptive methods was reported by 51% of respondents; however, 75% of residents reported a desire for more training about contraception. CONCLUSIONS: Internal medicine residents commonly care for women of reproductive age but infrequently assess or address contraceptive needs. Further training on how to provide contraception is desired by many internal medicine residents.


Subject(s)
Contraceptive Agents, Female/therapeutic use , Counseling/education , Family Planning Services/education , Internal Medicine/education , Internship and Residency/statistics & numerical data , Practice Patterns, Physicians'/statistics & numerical data , Preconception Care/standards , Women's Health Services/standards , Attitude of Health Personnel , Clinical Competence , Counseling/standards , Counseling/statistics & numerical data , Family Planning Services/standards , Family Planning Services/statistics & numerical data , Female , Health Care Surveys , Humans , Internship and Residency/standards , Los Angeles , Male , Patient Education as Topic , Preconception Care/statistics & numerical data , Program Evaluation , Surveys and Questionnaires , Women's Health Services/statistics & numerical data
5.
Clin Infect Dis ; 41(1): 128; author reply 128-9, 2005 Jul 01.
Article in English | MEDLINE | ID: mdl-15937780
SELECTION OF CITATIONS
SEARCH DETAIL
...